Medical device and digital healthcare group Adherium will supply its Hailie medical patient sensors and software to drug developer AstraZeneca where they will play a role in an upcoming clinical study in the United States.
The company will develop a bespoke version of its Hailie sensor to track the usage of inhaler medications via the patient participants mobile phones.
The Hailie sensor attaches to a patient’s medicine inhaler, monitoring usage, reminding patients if they miss a dose, and making data available to physicians.
Hailie sensors are compatible with drugs Symbicort HFA, Ventolin HFA, Advair HFA, Flovent HFA, ProAir HFA, Bevespi Aerosphere, Symbicort Turbuhaler, Bricanyl Turbuhaler, Advair Diskus, Flovent Diskus, and Handihaler medications.
Adherium will earn US $650,000 revenue in FY22 with further support services provided over the two year study.
CEO Rick Legleiter said: “Adherium has a longstanding clinical study relationship with AsteaZeneca to support the collection of of objective clinical data using Adherium’s Hailie technology.
“This is welcome revenue as Adherium progresses its strategy focusing on a provider and payor model and expanding its revenue base over multiple clinical channels.”
Subscribe to our free @AuManufacturing newsletter here.